Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;75(10):1743-8.
doi: 10.1136/annrheumdis-2015-208024. Epub 2016 Mar 25.

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis

Collaborators, Affiliations

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis

Rucsandra Dobrota et al. Ann Rheum Dis. 2016 Oct.

Abstract

Objectives: Improvement of skin fibrosis is part of the natural course of diffuse cutaneous systemic sclerosis (dcSSc). Recognising those patients most likely to improve could help tailoring clinical management and cohort enrichment for clinical trials. In this study, we aimed to identify predictors for improvement of skin fibrosis in patients with dcSSc.

Methods: We performed a longitudinal analysis of the European Scleroderma Trials And Research (EUSTAR) registry including patients with dcSSc, fulfilling American College of Rheumatology criteria, baseline modified Rodnan skin score (mRSS) ≥7 and follow-up mRSS at 12±2 months. The primary outcome was skin improvement (decrease in mRSS of >5 points and ≥25%) at 1 year follow-up. A respective increase in mRSS was considered progression. Candidate predictors for skin improvement were selected by expert opinion and logistic regression with bootstrap validation was applied.

Results: From the 919 patients included, 218 (24%) improved and 95 (10%) progressed. Eleven candidate predictors for skin improvement were analysed. The final model identified high baseline mRSS and absence of tendon friction rubs as independent predictors of skin improvement. The baseline mRSS was the strongest predictor of skin improvement, independent of disease duration. An upper threshold between 18 and 25 performed best in enriching for progressors over regressors.

Conclusions: Patients with advanced skin fibrosis at baseline and absence of tendon friction rubs are more likely to regress in the next year than patients with milder skin fibrosis. These evidence-based data can be implemented in clinical trial design to minimise the inclusion of patients who would regress under standard of care.

Keywords: Epidemiology; Outcomes research; Systemic Sclerosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Percentage of progressors and regressors per baseline modified Rodnan skin score (mRSS) range. Patients with lower skin score are more likely to progress, whereas those with higher skin scores are much more likely to regress. (B) Sensitivity for progression and regression depending on different cut-off values for baseline mRSS.

Comment in

Similar articles

Cited by

References

    1. Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007;9:151–7. 10.1007/s11926-007-0010-5 - DOI - PubMed
    1. Wiese AB, Berrocal VJ, Furst DE, et al. . Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. Arthritis Care Res (Hoboken) 2014;66:1731–9. 10.1002/acr.22339 - DOI - PMC - PubMed
    1. Lafyatis R. Application of biomarkers to clinical trials in systemic sclerosis. Curr Rheumatol Rep 2012;14:47–55. 10.1007/s11926-011-0216-4 - DOI - PMC - PubMed
    1. Maurer B, Graf N, Michel BA, et al. . Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2015;74:1124–31. 10.1136/annrheumdis-2014-205226 - DOI - PubMed
    1. Amjadi S, Maranian P, Furst DE, et al. . Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009;60:2490–8. 10.1002/art.24681 - DOI - PMC - PubMed

Publication types